Cyclin-dependent kinases 4 and 6 (CDK4/6) have emerged as crucial therapeutic targets in breast cancer treatment, particularly for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) subtypes [5]. Here, ERBB2 is linked to breast carcinoma.